| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Rapid Micro Biosystems, Inc. Class A Common Stock$2.06
-0.02 (-0.94%)
Market Cap
96.38 M
EPS
-1.06
P/E Ratio
-2 $
Value Trade
118.80 K
SEC Financials
Q1 2026Dilution Risk
Revenue
8.00 M
R&D Expenses
3.36 M
Operating CF
-15.06 M
Total Assets
62.36 M
Total Liabilities
41.97 M
Equity
20.40 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
22.95 M
Monthly Burn
5.02 M
Runway
2.2 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
198.55 K
52 Week Range
2 - 4.94
% held by Insiders
46.94 %
% held by Institutions
20.44 %
Enterprise Value
81.96 M
Total Shares
41.26 M
Short %
3.19 %
Float Shares
18.61 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RPID
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RPID Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-RPID
Aug 4, 2026▼ -0.9%today
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rapid Micro Biosystems announced the grant of 90,000 restricted stock units and a non-qualified stock option for a new employee as part of its Inducement Plan. The grants were approved by independent directors in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $2.12 per share and will vest over a period, while the RSUs will vest annually over three years.
Read more →-RPID
Jul 23, 2026Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
Rapid Micro Biosystems will announce its second quarter 2026 financial results on August 7, 2026. The announcement will be accompanied by a webcast conference call at 8:30 a.m. ET, allowing stakeholders to engage with the management team. The company specializes in automation solutions for healthcare product manufacturing.
Read more →-RPID
Jun 10, 2026Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rapid Micro Biosystems announced the grant of 60,000 restricted stock units (RSUs) to a new employee as an inducement for employment. This grant, approved under Nasdaq Listing Rule 5635(c)(4), is part of the company's strategy to attract talent. The RSUs will vest over three years, contingent on the employee's continued employment.
Read more →-RPID
May 19, 2026Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
Rapid Micro Biosystems has announced the pricing of an underwritten offering of approximately $32 million, which includes shares of Class A common stock and accompanying warrants. The offering aims to raise about $9.8 million initially, with potential additional proceeds of $21.7 million if all warrants are exercised. The offering is expected to close on May 20, 2026, subject to customary conditions.
Read more →-RPID
May 13, 2026Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
Rapid Micro Biosystems reported a total revenue of $8.0 million for Q1 2026, an 11% increase from the previous year. Product revenue saw a significant rise of 36%, while recurring revenue grew by 28%. Despite these gains, the company experienced a net loss of $14.3 million, up from $11.3 million in Q1 2025. The company reaffirmed its full-year revenue guidance of $37 million to $41 million.
Read more →-RPID
May 6, 2026Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
Rapid Micro Biosystems, Inc. will announce its first quarter 2026 financial results on May 13, 2026. Following the announcement, the management team will host a webcast conference call to discuss the results. The company specializes in automation solutions for the healthcare industry, particularly in microbial quality control testing.
Read more →-RPID
Mar 12, 2026▼ -21.8%on this news· ran to -35% by day 1
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance Reports record fourth quarter 2025 total revenue of $11.3 million, representing 37% growth compared to
Rapid Micro Biosystems reported strong financial performance for Q4 and the full year 2025, with quarterly revenue reaching $11.3 million, marking a 37% growth year-over-year. The company also forecasts continued growth in 2026, estimating total revenue between $37.0 million and $41.0 million, driven by additional Growth Direct system placements. However, despite these positive indicators, there were challenges including a net loss of $12.5 million in the fourth quarter and a decrease in gross margin percentage.
Read more →-RPID
Feb 25, 2026▲ +6.3%on this news
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
Rapid Micro Biosystems, Inc. will announce its fourth quarter and full year 2025 financial results on March 12, 2026. The announcement will be made prior to market opening, followed by a webcast conference call at 8:30 a.m. ET. The company specializes in automation solutions for the healthcare sector, enhancing manufacturing efficiency and safety.
Read more →-RPID
Jan 14, 2026▲ +21.1%on this news· ran to +45% by day 3
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Rapid Micro Biosystems announced preliminary unaudited revenue results for Q4 and full year 2025, reporting record revenue of approximately $11.3 million for Q4, a 37% increase year-over-year. The full year revenue is expected to reach approximately $33.6 million, reflecting a 20% growth. The company attributes this success to strong demand for its Growth Direct systems and services.
Read more →-RPID
Jan 13, 2026Document Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approx
Rapid Micro Biosystems announced impressive preliminary unaudited financial results for the fourth quarter and full year 2025. For Q4, the company projects revenues of around $11.3 million, reflecting a 37% increase year-over-year. Additionally, the full year revenue is expected to be approximately $33.6 million, a 20% growth from the previous year. Notably, the company secured a record order from a top biopharma client, enhancing their manufacturing efficiency. The results also highlight significant recurring revenue growth, indicating the company's strong market position and potential for continued expansion.
Read more →-RPID
Nov 7, 2025▲ +12.7%on this news· ran to +51% by day 3
Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance Reports third quarter 2025 total revenue of $7.8
Rapid Micro Biosystems has reported its third-quarter financial results for 2025, achieving a total revenue of $7.8 million, an increase of 3% over the same quarter last year. The company experienced significant growth in recurring revenue, up by 32%, and secured its largest multi-system customer order in history. As a result, Rapid Micro has raised its full-year revenue guidance to at least $33 million. However, the company reported a net loss of $11.5 million, slightly exceeding last year's loss, with a gross margin improvement to 9%. Despite the losses, the overall outlook remains positive due to increased demand and innovative product placements.
Read more →-RPID
Aug 12, 2025▼ -17.8%on this news
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurrin
Rapid Micro Biosystems reported its second quarter 2025 financial results, revealing a total revenue of $7.3 million, a 10% increase from the previous year. Recurring revenue showed a robust 15% growth, alongside a notable improvement in gross margin at 4%. The company announced a five-year, $45 million term loan facility, which enhances its financial stability and supports future growth initiatives. Despite these positive metrics, the company continues to face challenges, with a net loss of $11.9 million.
Read more →-RPID
Jun 17, 2025Dear RMB Team Members and Shareholders I am writing on a personal note to let you know that I was recently diagnosed with a treatable form of Lymphoma. The good news is that I have an excellent care team and my doctors h
The CEO of RMB has announced a personal health update, revealing a recent diagnosis of a treatable form of Lymphoma. Despite limiting in-person office time during the expected four-month treatment, the CEO plans to actively manage business operations. The leadership team and board have expressed full support, and the CEO remains optimistic about the company’s continued performance and patient care initiatives.
Read more →-RPID
May 9, 2025▲ +25.7%on this news
Rapid Micro Biosystems Reports First Quarter 2025 Financial Results Reports first quarter 2025 total revenue of $7.2 million, representing 28% growth compared to the first quarter of 2024. Reports record quarterly servic
Rapid Micro Biosystems reported strong first-quarter financial results for 2025, with total revenue reaching $7.2 million, a 28% increase from the previous year. The company announced significant gross margin improvements and record service revenue driven by enhanced validation activities. A distribution agreement with Merck KGaA was also highlighted as a key development. However, the company continues to face challenges, including ongoing net losses.
Read more →-RPID
Mar 4, 2025rpidxpresentation Rapid Micro Biosystems TD Cowen 45th Annual Health Care Conference Robert Spignesi, President & CEO
At the TD Cowen 45th Annual Health Care Conference, Rapid Micro Biosystems discussed their forward-looking strategies and impressive growth metrics. The company announced a 25% increase in total revenue for FY 2024, achieving a record for quarterly and yearly performance. They highlighted successful collaborations with Merck KGaA (MilliporeSigma) and Lonza, aimed at expanding their products into new markets. Despite these successes, the company acknowledged ongoing financial challenges and emphasized their commitment to achieving positive cash flow by the end of 2027.
Read more →-RPID
Feb 27, 2025▲ +22.1%on this newsshared move
Document Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany Significantly extends commercial reach of Growth Direct through e
Rapid Micro Biosystems has entered a five-year global distribution and collaboration agreement with Merck KGaA's Life Science business. This partnership grants Merck co-exclusive rights to sell Growth Direct systems, enhancing Rapid Micro's commercial reach in various sectors including pharmaceuticals and food. The agreement aims to explore cost efficiencies and joint product development. It positions both companies to maximize their market offerings and accelerate innovation in manufacturing quality control.
Read more →-RPID
Jan 16, 2025▼ -5.1%on this news
rpidxpresentation Rapid Micro Biosystems 43rd Annual J.P. Morgan Healthcare Conference Rob Spignesi, President & CEO
At the 43rd Annual J.P. Morgan Healthcare Conference, Rapid Micro Biosystems presented strong financial results, highlighting a revenue increase of approximately 30% in Q4 2024 and 25% for the full year. The company noted over 160 cumulative placements of its Growth Direct systems and a shift to positive gross margins for the last two quarters. CEO Rob Spignesi emphasized ongoing efforts to drive sustainable long-term growth and announced a significant collaboration with Lonza aimed at enhancing microbial quality control processes across the industry. However, the company continues to face challenges including achieving its business objectives and managing substantial historical losses.
Read more →-RPID
Jan 14, 2025Document Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue Fourth quarter 2024 total revenue expected to be a record at approximately $8.2 million, representing growth of ap
Rapid Micro Biosystems has announced preliminary unaudited revenue figures for the fourth quarter and full year of 2024. The company expects record fourth quarter revenue of approximately $8.2 million, which represents a year-over-year growth of about 30%. Additionally, the full year revenue is projected to be around $28.1 million, showing growth of roughly 25% compared to the previous year. The company has also reported significant advancements in its collaboration with Lonza, integrating technology that enhances environmental monitoring within manufacturing processes.
Read more →-RPID
Nov 1, 2024Rapid Micro Biosystems Reports Third Quarter 2024 Financial Results Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24% compared to the third quarter of 2023 Placed seven Growth Direct s
Rapid Micro Biosystems reported a record revenue of $7.6 million for the third quarter of 2024, marking a 24% increase from 2023. The company achieved its highest number of system placements since 2021, including a multi-system order from a top global pharma customer. Gross margins turned positive at 8%, reflecting a 35-point improvement year-over-year. Despite a continuing net loss of $11.3 million, Rapid Micro maintains its revenue guidance for the full year, projecting over $27 million in total revenue.
Read more →-RPID
Aug 2, 2024▲ +17.3%on this news
Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023 150th Growth Direct system placed
Rapid Micro Biosystems reported a strong second quarter of 2024 with record revenues of $6.6 million, marking a 32% increase from the previous year. The company successfully placed its 150th Growth Direct system and improved gross margins significantly. An operational efficiency program is underway, aimed at achieving positive cash flow without additional financing. Despite a net loss of $12.6 million, the company reaffirms its revenue guidance for the full year 2024, projecting at least $27 million in total revenue.
Read more →-RPID
May 3, 2024▼ -10.1%on this news
Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total reven
Rapid Micro Biosystems reported its financial results for the first quarter of 2024, showing a revenue increase of 11% year-over-year to $5.6 million. The company achieved a significant 15% growth in recurring revenue, attributed to higher consumable sales and service contracts. However, despite this growth, Rapid Micro posted a net loss of $13.3 million. The company reaffirmed its full-year revenue guidance, anticipating at least 20% growth compared to 2023, alongside the planned launch of its Growth Direct Rapid Sterility platform.
Read more →-RPID
Jan 11, 2024Document Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue Full year 2023 total revenue expected to be between $22.4 million and $22.6 million, representing growth of over 3
Rapid Micro Biosystems (Nasdaq: RPID) announced preliminary unaudited revenue for the fourth quarter and full year 2023, expecting total revenues between $22.4 million and $22.6 million, indicating over 30% growth compared to the previous year. The fourth quarter alone may see revenues between $6.2 million and $6.4 million, marking an increase of approximately 45% year-over-year. The company has also placed six new Growth Direct systems and achieved placements with every commercially approved CAR-T therapy manufacturer. Rapid Micro intends to provide a detailed financial update and outlook during the webcast planned for March 2024.
Read more →-RPID
Nov 3, 2023▲ +7.4%on this news
Rapid Micro Biosystems Reports Third Quarter 2023 Financial Results Reports third quarter 2023 total revenue of $6.1 million, representing growth of 30% compared to third quarter 2022 Reaffirms full year 2023 total reven
Rapid Micro Biosystems, Inc. reported a strong performance in its third quarter of 2023, achieving total revenue of $6.1 million, which is a 30% increase compared to the same quarter in 2022. The company reaffirmed its full-year revenue guidance, projecting at least $22 million, also reflecting 30% growth year-over-year. Amid increasing revenues, the company still faced a net loss of $13.4 million but indicated operational improvements and strong demand for its products, including new system placements. The company also reported a significant increase in recurring revenue as it continues to expand its customer base among key global pharmaceutical manufacturers.
Read more →-RPID
Aug 4, 2023Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results Reports second quarter 2023 total revenue of $5.0 million, representing growth of 30% compared to second quarter 2022 Reaffirms full year 2023 total re
Rapid Micro Biosystems reported a significant financial result for the second quarter of 2023, with total revenue reaching $5.0 million, reflecting a 30% increase compared to the previous year. Recurring revenue also saw a notable rise of 44%, attributed to record consumable sales and effective operational execution. Despite these positive outcomes, the company reported a net loss of $14.0 million, which was higher than the previous year's loss, primarily due to increased costs of revenue. The company reaffirmed its full-year revenue guidance, projecting at least $22 million for 2023.
Read more →-RPID
May 5, 2023Rapid Micro Biosystems Reports First Quarter 2023 Financial Results Reports first quarter 2023 total revenue of $5.0 million, representing growth of 21%, compared to first quarter 2022 Reaffirms full year 2023 total reve
Rapid Micro Biosystems announced a 21% increase in total revenue for Q1 2023, amounting to $5.0 million compared to Q1 2022. The company also reported a 22% growth in recurring revenue and reaffirmed its guidance for full-year 2023 revenue of at least $22 million. Additionally, three new systems were placed, with two customer systems validated during the quarter. The appointment of Michael Wysocki as Senior VP of Sales and Marketing was also highlighted.
Read more →-RPID
Jan 12, 2023Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Full year 2022 commercial revenue expected to be between $17.0 million and $17.2 million Finished 2022 with approximately $
Rapid Micro Biosystems has announced preliminary unaudited revenue for the fourth quarter and full year 2022, projecting full-year commercial revenue between $17.0 million and $17.2 million. The company has seen operational success with the placement and validation of several Growth Direct systems, as well as the addition of new prominent pharmaceutical customers. Rapid Micro aims to leverage its innovations to capture market opportunities, supported by a strong cash position of approximately $140 million.
Read more →-RPID
Dec 1, 2022▼ -21%on this news
Rapid Micro Biosystems Concludes Review of Strategic Alternatives
Rapid Micro Biosystems Concludes Review of Strategic Alternatives LOWELL, Mass., December 1, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to fac
Read more →-RPID
Nov 10, 2022Rapid Micro Biosystems Reports Third Quarter 2022 Financial Results Reports third quarter 2022 commercial revenue of $4.7 million Delivered year-over-year recurring revenue growth of 34% Reaffirms full year 2022 commerci
Rapid Micro Biosystems Reports Third Quarter 2022 Financial Results Reports third quarter 2022 commercial revenue of $4.7 million Delivered year-over-year recurring revenue growth of 34% Reaffirms full year 2022 commercial revenue guidance of at least $17.0 million LOWELL, Ma
Read more →-RPID
Aug 12, 2022▼ -6.1%on this news
Rapid Micro Biosystems Provides Business Update and Reports Second Quarter 2022 Financial Results Reports second quarter 2022 commercial revenue of $3.9 million Lowers full year 2022 commercial revenue guidance to at lea
Rapid Micro Biosystems Provides Business Update and Reports Second Quarter 2022 Financial Results Reports second quarter 2022 commercial revenue of $3.9 million Lowers full year 2022 commercial revenue guidance to at least $17.0 million Implements organizational restructuring
Read more →-RPID
May 10, 2022▼ -7.1%on this news· ran to -19% by day 1
Rapid Micro Biosystems Reports First Quarter 2022 Financial Results Reports first quarter 2022 commercial revenue of $4.2 million Reaffirms full year 2022 commercial revenue outlook range of $27 million to $32 million, r
Rapid Micro Biosystems Reports First Quarter 2022 Financial Results Reports first quarter 2022 commercial revenue of $4.2 million Reaffirms full year 2022 commercial revenue outlook range of $27 million to $32 million, representing growth of approximately 25% to 50% LOWELL, Ma
Read more →-RPID
Mar 4, 2022▼ -5.6%on this news
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2021 Financial Results and Reaffirms Full Year 2022 Guidance Reports fourth quarter 2021 total revenue of $5.2 million and commercial revenue of $4.9 million Re
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2021 Financial Results and Reaffirms Full Year 2022 Guidance Reports fourth quarter 2021 total revenue of $5.2 million and commercial revenue of $4.9 million Reports full year 2021 total revenue of $23.2 million and co
Read more →-RPID
Jan 13, 2022▲ +10.7%on this news
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook Full year 2021 commercial revenue expected to be between $21.3 million and $21.7 million
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue and Provides 2022 Revenue Outlook Full year 2021 commercial revenue expected to be between $21.3 million and $21.7 million Full year 2022 commercial revenue outlook between $27 mill
Read more →-RPID
Dec 23, 2021Rapid Micro Biosystems Announces Appointment of Inese Lowenstein to Board of Directors
Rapid Micro Biosystems Announces Appointment of Inese Lowenstein to Board of Directors LOWELL, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automati
Read more →-RPID
Nov 11, 2021Rapid Micro Biosystems Reports Third Quarter 2021 Financial Results Reports third quarter 2021 total revenue of $6.9 million and commercial revenue of $6.3 million Reaffirms full-year 2021 commercial revenue outlook of a
Rapid Micro Biosystems Reports Third Quarter 2021 Financial Results Reports third quarter 2021 total revenue of $6.9 million and commercial revenue of $6.3 million Reaffirms full-year 2021 commercial revenue outlook of at least $24.0 million, representing at least 70% year-over
Read more →-RPID
Aug 26, 2021Rapid Micro Biosystems Reports Second Quarter 2021 Financial Results and Provides Business Update and Full Year 2021 Outlook Reports second quarter 2021 commercial revenue of $5.7 million, representing 135% year-over-yea
Rapid Micro Biosystems Reports Second Quarter 2021 Financial Results and Provides Business Update and Full Year 2021 Outlook Reports second quarter 2021 commercial revenue of $5.7 million, representing 135% year-over-year growth Issues full-year 2021 outlook for commercial r
Read more →Competitive Position
How RPID ranks across every disease it competes inCompetitive Position is a premium feature
See how RPID ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial